Galectin Therapeutics (GALT -10.7%) drops after reporting Q3 results.
The company says "five of the eight patients have been enrolled and infused" in a Phase 1 study of GR-MD-02 in NASH.
Data from the first cohort of patients is due early next year assuming "all goes as expected."
As of September 30, GALT had $9.7M in cash which the company says should last "into Q3 of 2014." (PR)